New Zealand Proposes Funding Letermovir to Prevent Infection After Stem Cell Transplants
Associate Health Minister David Seymour and Health Minister Simeon Brown support Pharmac’s proposal to fund letermovir from May 2026 to prevent serious CMV infections in stem cell transplant patients and those with severe immunosuppression. This initiative aims to improve patient outcomes by reducing complications, hospital stays, and healthcare system pressure, aligning with the Government’s commitment to expanding stem cell transplant capacity and enhancing cancer treatment access. Pharmac is currently seeking public feedback on the proposal, inviting input from affected patients, families, health professionals, and advocacy groups.